VPHIF (Valeo Pharma) Equity-to-Asset: -1.96 (As of Jul. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VPHIF Valeo Pharma Inc VPHIF
12 GF Score
Price $0.00
View Full Analysis

What is Valeo Pharma Equity-to-Asset?

Valeo Pharma VPHIF -99.00% 12 Equity-to-Asset is -1.96 as of Jul. 2024. GuruFocus rates VPHIF with a GF Score™ of 12/100.

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Valeo Pharma's Total Stockholders Equity for the quarter that ended in Jul. 2024 was $-45.96 Mil. Valeo Pharma's Total Assets for the quarter that ended in Jul. 2024 was $23.48 Mil. Therefore, Valeo Pharma's Equity to Asset Ratio for the quarter that ended in Jul. 2024 was -1.96.

The historical rank and industry rank for Valeo Pharma's Equity-to-Asset or its related term are showing as below:

VPHIF's Equity-to-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.6
* Ranked among companies with meaningful Equity-to-Asset only.

Valeo Pharma  (OTCPK:VPHIF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Valeo Pharma Equity-to-Asset Related Terms

Valeo Pharma Equity-to-Asset Historical Data

* Premium members only.

The historical data trend for Valeo Pharma's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valeo Pharma Equity-to-Asset Chart

Valeo Pharma Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Equity-to-Asset
Get a 7-Day Free Trial -0.00 0.28 0.10 -0.31 -0.98

Valeo Pharma Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.77 -0.98 -1.17 -1.59 -1.96

VPHIF vs ZTS: Equity-to-Asset Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Valeo Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valeo Pharma Equity-to-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Valeo Pharma's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Valeo Pharma's Equity-to-Asset falls into.


VPHIF
12GF Score
Valeo Pharma Inc VPHIF
Equity-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valeo Pharma Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Valeo Pharma's Equity to Asset Ratio for the fiscal year that ended in Oct. 2023 is calculated as

Equity to Asset (A: Oct. 2023 )=Total Stockholders Equity/Total Assets
=-29.417/30.052
=-0.98

Valeo Pharma's Equity to Asset Ratio for the quarter that ended in Jul. 2024 is calculated as

Equity to Asset (Q: Jul. 2024 )=Total Stockholders Equity/Total Assets
=-45.963/23.476
=-1.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Equity-to-Asset →
What does a Equity-to-Asset of -1.96 mean?
Valeo Pharma (VPHIF) has a Equity-to-Asset of -1.96 as of Jul. 2024. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Valeo Pharma and its competitors.
Is Valeo Pharma's Equity-to-Asset too high?
Valeo Pharma's current Equity-to-Asset is -1.96. Overall, Valeo Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Valeo Pharma's Equity-to-Asset compare to ZTS?
Valeo Pharma's Equity-to-Asset of -1.96 can be compared against companies in the Drug Manufacturers industry. The industry median Equity-to-Asset is 0.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Valeo Pharma and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valeo Pharma's current Equity-to-Asset is -1.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valeo Pharma stock overvalued right now?
Valeo Pharma (VPHIF) has a current Equity-to-Asset of -1.96. The current Equity-to-Asset is -1.96. Valeo Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Valeo Pharma (VPHIF), the current Equity-to-Asset is -1.96 as of Jul. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Valeo Pharma Business Description

Address 16667, Hymus Boulevard, Kirkland, QC, CAN, H9H 4R9
Valeo Pharma Inc is a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing, or similar arrangements. The company operates in two divisions: Branded prescription products and hospital specialty products. Its product portfolio includes medicines for Respiratory/Allergy, Ophthalmology, Neurology, and Oncology.
12GF Score

Get the complete analysis for VPHIF

Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price